Abstract
The therapy for patients with hepatitis C, for more than a decade, was based in the use of conventional interferon (IFN) or pegylated interferon (IFN-PEG) combined with ribavirin (RBV), administered for 24 or 48 weeks depending on the infecting genotype. Due to this, it is of extreme importance to recognize the mechanism behind the therapy, because even today its real functioning is unkno…